Vol. 18/No. 15

The growing use of next-generation sequencing has only recently revealed the neurotrophic tropomyosin receptor kinase (NTRK) gene presence across a wide range of tumor types and piqued interest in their potential as anticancer targets.

A comparison of the genomic risk profiles of patients with low-risk prostate cancer who are candidates for active surveillance against higher-risk patients, discovered that substantial genomic heterogeneity exists among patients with prostate cancer.

James F. Holland, MD, reminisces on nearly 70 years of practicing medicine.

Selinexor (KPT-330), a small-molecule inhibitor with a novel mechanism of action, is being investigated in patients with multiple myeloma who have become refractory to the many new options that have been introduced in recent years for patients with the malignancy.

The recent approval of 2 immunotherapies for the treatment of certain patients with tumors that exhibit microsatellite instability has propelled the emerging biomarker into clinical practice, prompting calls for broader genetic testing.

The introduction of targeted therapies has transformed HER2-positive breast cancer from an aggressive disease with poor outcomes to a highly manageable disease with potential for long-term survival.

Despite the promise of immunotherapy for treating patients with advanced cancers, the success of using such therapies for progressive gastrointestinal malignancies such as colorectal liver metastases (CRLM) has been limited so far.

In the cancer management arena, the term “clinical benefit” has unfortunately achieved a problematic status.